Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00089895
Status:
COMPLETED
Last Update Posted:
2024-05-17
First Post:
2004-08-17
Brief Title:
EARLY ACS Early Glycoprotein IIbIIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome Study P03684AM2COMPLETED
Sponsor:
Organon and Co
Organization:
Organon and Co
Study Overview
Official Title:
Early Glycoprotein IIbIIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome A Randomized Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevation Acute Coronary Syndrome EARLY ACS
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if early INTEGRILIN eptifibatide therapy in patients with non-ST-segment elevation acute coronary syndrome ACS reduces the occurence of death heart attack and urgent cardiac intervention surgery compared to placebo with delayed provisional use of eptifibatide
Detailed Description:
This study will enroll patients who experience symptoms of acute coronary syndrome experiencing chest pain at rest with episodes lasting at least 10 minutes and who are planned to undergo invasive surgical procedures after being given study drug for 12 to 96 hours There are two different treatment groups in this study approximately half of the patients will go to each group and the likelihood of receiving study drug vs placebo is 5050 like tossing a coin Medications that are standard of care will be provided to the patients all patients will be given aspirin and standard hospital doses of one of two other blood thinning drugs - unfractionated heparin UFH or low-molecular-weight heparin Which one patients receive is at the discretion of the Investigator
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None